Skip to main content
. 2006 Dec;2(4):377–388. doi: 10.2147/tcrm.2006.2.4.377

Table 4.

CALGB Azacytidine trials

Trial 8421 Phase I Trial 8921 Phase II Trial 9221 RCT
Intravenous Subcutaneous Supportive care Azacytidine
Patient evaluated 43 68 92 99
CR 5 (12%) 8 (12%) 0 (0%) 7(7%)*
PR 11 (25%) 10 (15%) 0 (0%) 16 (16%)+
Improved 5 (12%) 18 (27%) 5 (5%) 37 (37%)+
Total response 21 (49%) 36 (53%) 5 (5%) 60 (60%)+
*

Note: p=0.01,

+

p<0.0001

Abbreviations: CALGB, Cancer And Leukemia Group B; CR, complete response; PR, partial response, RCT, randomized controlled trial.